ArticleAlimentary pharmacology & therapeutics2021
Immune-mediated diseases and risk of Crohn's disease or ulcerative colitis: a prospective cohort study.
Article in Alimentary pharmacology & therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Association between OLD and IBD: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- MTX-induced gastrointestinal reactions in RA: Prevotella enrichment, gut dysbiosis, and PI3K/Akt/Ras/AMPK pathways.Clinical rheumatology · 2025Article
- Regulatory Role of IL6 in Immune-Related Adverse Events during Checkpoint Inhibitor Treatment in Melanoma.International journal of molecular sciences · 2024Article
- Risk Factors for the Development of and Outcomes After Diagnosis of Autoimmune Alopecia Areata in Patients with Inflammatory Bowel Diseases.Digestive diseases and sciences · 2024Article
- Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.Arthritis research & therapy · 2024Article
- Calprotectin Is Associated with HETE and HODE Acids in Inflammatory Bowel Diseases.Journal of clinical medicine · 2023Article
- The Relationship Between Rosacea and Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Dermatology and therapy · 2023Review
- A Single-Center Experience with Dupilumab for Atopic or Psoriasiform Dermatitis in Patients with Inflammatory Bowel Disease.Digestive diseases and sciences · 2023Article
- Risk Factors for Developing Inflammatory Bowel Disease Within and Across Families with a Family History of IBD.Journal of Crohn's & colitis · 2023Article
- Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study: Classification: Epidemiology.The British journal of dermatology · 2022Article
- siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: A preliminary review.Cell biology international · 2022Review
- Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure.Dermatology and therapy · 2022Article
- Inflammatory Bowel Disease Management during the COVID-19 Pandemic: A Literature Review.Middle East journal of digestive diseases · 2022Review
- Editorial: immune-mediated diseases-are we closer to disease-defining molecular signatures?Alimentary pharmacology & therapeutics · 2021Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAlthough immune-mediated diseases (IMDs) including inflammatory bowel diseases (IBDs) are known to cluster, to what extent this is due to common environmental influences is unknown.
aimTo examine the incidence of IBD in individuals with another IMD.
methodsWe used data from the prospective Nurses' Health Study II cohort (1995-2017) to examine the effect of diagnoses of several common IMDs on subsequent risk of Crohn's disease (CD) or ulcerative colitis (UC) using Cox proportional hazards models, adjusting for detailed diet and lifestyle confounders.
resultsWe documented 132 cases of CD and 186 cases of UC over 2 016 163 person-years of follow-up (median age at IBD diagnosis 50 years). Compared to participants with no history of IMD, the HRs of CD for those with 1 and ≥ 2 IMDs were 2.57 (95% CI 1.77-3.74) and 2.74 (95% CI 1.36 to 5.49), respectively (P
conclusionsIndividuals with one or more IMDs are at an increased risk for CD but not UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.